Which long-term road for GlaxoSmithKline

Comment icon 0 Comments
GlaxoSmithKline (GSK), the British pharmaceutical company with U.S. operations in the Philadelphia area, reported 2015 first quarter earnings... Read more

Drug pricing: The problem and some band-aids

Comment icon 0 Comments
Two stories surfaced this week that provide more examples of how increasing drug prices have gotten totally out of hand. In the first one... Read more

Self-dealing physicians and a bad trade deal

Comment icon 0 Comments
The costs of health care and affordable access to it are made worse by high drug prices that keep rising many times faster than the cost living... Read more

Two questionable ways to develop new drugs

Comment icon 0 Comments
A substantial and growing number of people working in pharma R&D are painfully aware that the industry's “strategic partnering”... Read more

Can polio cure cancer? If it's one dose and done, will pharma try it?

Comment icon 0 Comments
This is definitely a week when the media's spotlight has been shining on cancer. Each evening between Monday and Wednesday, PBS has been running... Read more

An oncologist's explanation for unaffordable drug prices

Comment icon 0 Comments
Dr. Hagop Kantarjian is an oncologist who spends his days treating leukemia patients at Houston's M.D. Anderson Cancer Center and conducting... Read more

Layoffs and site closings more than just a reshuffle

Comment icon 0 Comments
John La Mattina worked at Pfizer for thirty years, eventually becoming their head of R&D in 2004. He held that position for four years... Read more

Did Sanofi pick l'homme juste?

Comment icon 0 Comments
Last month the French pharma company, Sanofi, named Olivier Brandicourt as its new CEO. Brandicourt had been the chief executive of Bayer's... Read more